Opinion|Videos|October 11, 2024
Complement Inhibitors in NMOSD
Author(s)Sean Pittock, MD
Sean Pittock, MD, discusses how complement inhibitors are positioned in the treatment landscape of neuromyelitis optica spectrum disorder, providing an overview of ravulizumab, the most recent FDA-approved treatment, including its development rationale, half-life, dosing regimen, and new signals from the recently presented 138-week long-term extension data at EAN 2024.
Advertisement
Video content above is prompted by the following:
- Where do complement inhibitors fit in the treatment landscape of neuromyelitis optica spectrum disorder (NMOSD)? Which complement inhibitors are approved for NMOSD?
- Please provide an overview of ravulizumab, the most recent FDA-approved treatment for NMOSD, the rationale for its development, half-life, and dosing regimen.
- Long-term extension (138-week) data with ravulizumab were recently presented at EAN 2024.
- Are there any new signals in the long-term extension study?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
3
NeurologyLive® Brain Games: September 14, 2025
4
This Week on NeurologyLive® — September 15, 2025
5